PMEF
RLAY icon

Point72 Middle East FZE’s Relay Therapeutics RLAY Stock Holding History

Point72 Middle East FZE’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-58,747
Closed -$494K – 1820
2023
Q3 		$494K Buy
+58,747
New +$632K 0.02% 805

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Point72 Middle East FZE's RLAY Position: Q4 2023 in Review

Point72 Middle East FZE sold out of Relay Therapeutics (RLAY) in Q4 2023, closing a stake of 58,747 shares — an estimated $494K sold.

Point72 Middle East FZE first reported a position in RLAY in Q3 2023 and held it in 1 quarter. The position peaked at $494K in Q3 2023. 177 funds tracked by Wall St. Rank hold RLAY as of Q4 2023.

  • Point72 Middle East FZE reported no remaining Relay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Point72 Middle East FZE sold 58,747 Relay Therapeutics shares in Q4 2023, an estimated $494K.
  • Point72 Middle East FZE first reported a position in Relay Therapeutics in Q3 2023 and held it in 1 quarter.
  • Point72 Middle East FZE's Relay Therapeutics position peaked at $494K in Q3 2023.
  • 177 funds tracked by Wall St. Rank held Relay Therapeutics as of Q4 2023.

Based on Point72 Middle East FZE's 13F filing for Q4 2023, filed 14 Feb 2024.